Loading clinical trials...
Loading clinical trials...
Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function
Conditions
Interventions
Raltegravir, Darunavir/r
Locations
1
Japan
National Center for Global Health and Medicine
Shinjuku, Tokyo, Japan
Start Date
February 1, 2011
Primary Completion Date
February 1, 2012
Completion Date
December 1, 2013
Last Updated
March 30, 2015
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
National Center for Global Health and Medicine, Japan
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions